Status:
COMPLETED
Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinjector (AI) on the Injection Pain Experiences in Healthy Volunteers
Lead Sponsor:
AbbVie
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The objective of this study is to assess the impact of different warm-up times of risankizumab autoinjector (AI) on the participant injection site pain experience in healthy adult volunteers.
Eligibility Criteria
Inclusion
- \- Body mass index (BMI) is \>= 18.0 to \<= 30.0 kg/m2.
Exclusion
- Any findings in the medical examination that are deviating from normal and judged as clinically relevant by the investigator.
- Any laboratory value outside the reference range that the investigator considers to be of clinical relevance.
- Any evidence of a concomitant disease judged as clinically relevant by the investigator.
- History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma), renal, hepatic, gastrointestinal, hematologic, or psychiatric disease or disorder, or any other uncontrolled medical illness.
Key Trial Info
Start Date :
September 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 7 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05274087
Start Date
September 15 2020
End Date
April 7 2021
Last Update
March 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Acpru /Id# 223662
Grayslake, Illinois, United States, 60030